Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Quinidine/dextromethorphan Treatment Report
What is Quinidine/dextromethorphan?

Neurodex is a combination of 30mg Dextromethorphan (found in cough medicine) and 30mg Quinidine made by Avanir Phamaceuticals. In a randomised, multicentre control trial the combination of these two agents was found to halve episodes of emotional lability relative to either agent alone. Read more...Click to read more below

Avanir's Quinidine/dextromethorphan site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Emotional lability 10 1
disease-related symptoms 1 0
Cramps 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
1 100%

Dosages

  daily 40 mg daily 50 mg daily 60 mg daily 90 mg daily 105 mg daily
  4 Number of Patients: 4 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Quinidine/dextromethorphan (multiple reasons could be selected)
Reason # Patients Percentage of patients
Expense
1 50% Expense: 50%
Course of treatment ended
1 50% Course of treatment ended: 50%

See all 2 patients who’ve stopped taking Quinidine/dextromethorphan

Currently Taking Quinidine/dextromethorphan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
0
4

Stopped Taking Quinidine/dextromethorphan

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
1
1

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

Report created on November 21, 2009.